MicroMatrix® Flex in Tunneling Wounds
← catalyst calendarSponsored by Integra LifeSciences Corporation (industry) · IART — their whole pipeline →.
Phase
Not applicable
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
25actual
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-12 | actual | When the study began enrolling |
| Primary completion | 2025-08-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-31 | actual | The whole study's end, after follow-up |
| First posted | 2024-10-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pressure Injury
- Venous Ulcer
- Necrotizing Soft Tissue Infection
- Diabetic Ulcers
- Draining Wound
Interventions
- Device: MicroMatrix® Flex
- Device: MicroMatrix® UBM Particulate
- Device: Cytal® Wound Matrix 2-Layer
Primary outcome
what the primary-completion date above is the date OFRelative rate of closure of a tunneling or undermining feature
measured At 12 weeks or skin graft visit
Permalink · IART's whole pipeline · Catalyst calendar · Every registered study · What changed